Washington, January 23: In view of the spike in COVID-19 infections globally, a recent study shed light on the strength, durability and breadth of neutralizing antibody responses generated by breakthrough infections in individuals vaccinated against SARS-CoV-2.

The findings were published in 'Cell', one of the scientific journals of Cell Press. Also Read | Omicron in Community Transmission Stage in India, Dominant in Multiple Metros, Says INSACOG.

Alexandra Walls and David Veesler in the Department of Biochemistry at the University of Washington in Seattle led the project. Characteristics of the Delta and Omicron coronavirus variants of concern included enhanced transmissibility and immune evasion even in non-immunologically naive individuals, compared to the ancestral pandemic coronavirus. Also Read | Winter Fitness Tips: How To Avoid Weight Gain and Stay Fit During Winters? Try These 5 Tricks.

These characteristics, and the waning of immunity from vaccines, have led to breakthrough infections in vaccinated individuals. For the most part, otherwise healthy people who were vaccinated against the SARS-CoV-2 usually did not have severe symptoms if they did end up contracting the virus.

The researchers wanted to understand what effect catching the virus after being vaccinated had on neutralizing antibodies, and to see how durable and broad these responses were. Their hope was that advancing such knowledge would help guide vaccination policies and pandemic mitigation strategies.

Through their project the researchers learned that the degree of antibody response depended on whether a person has had one, two, three, or four exposures to the spike protein through infection, vaccination, or a mixture of the two. The scientists also checked antibody responses in groups of individuals who had been vaccinated after having COVID-19, those who were previously vaccinated and experienced a breakthrough infection, those who were vaccinated only, and those who were boosted and therefore vaccinated three times.

Among their study subjects, those who had completed a three-vaccination protocol, and those who had been vaccinated after recovering from COVID-19, and those with a breakthrough infection after vaccination launched almost comparable neutralizing antibody responses, in terms of magnitude and breadth. Their serum binding and antibody neutralizing responses to the spike protein in the current pandemic coronavirus variants were much more potent and lasting than those generated by people who had received only two doses of COVID-19 vaccine or who had a previous infection not followed by vaccination.

This observation suggested that the increased number of exposures to SARS-CoV-2 antigens, either through infection and vaccination or triple vaccination, enhanced the quality of antibody responses.

The researchers also looked at how broad the elicited antibodies could be. They investigated neutralization of the divergent Omicron SARS-CoV-2 variant of concern, currently responsible for the majority of cases in the United States.

Their findings showed that boosted individuals (or those that have a mixture of infection and double vaccination) have neutralizing antibodies at similar levels to subjects vaccinated twice against the original ancestral strain. This suggested a large amount of immune evasion, but that vaccine boosters could help close the neutralizing antibody gap caused by Omicron.

Looking outside of the SARS-CoV-2 family showed a similar pattern, where repeated and multiple exposures improved the otherwise weak neutralizing antibody response to SARS-CoV. Finally, the authors did not identify improvements in antibody binding to common cold causing coronavirus spike proteins like OC43 or HKU1.

This suggested that repeated SARS-CoV-2 exposure does not improve spike reactivity to more divergent coronaviruses. These findings supported the development of broader sarbecovirus or coronavirus vaccines to be prepared in the event of a future spillover event.

The study groups consisted of about 15 people, from the Hospitalized or Ambulatory Adults with Respiratory Viral Infections, or HAARVI, project at the UW in Seattle. HAARVI, led by UW Medicine infectious disease physician Helen Chu, looked at recovered COVID-19 patients to study immune responses over time, to understand the long-term consequences of the infection, and to compare immune responses from vaccines and natural infections.

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)